TY - JOUR
T1 - Lutetium-177 Prostate-Specific Membrane Antigen Therapy
T2 - A Practical Review
AU - Jia, Angela Y.
AU - Kashani, Rojano
AU - Zaorsky, Nicholas G.
AU - Baumann, Brian C.
AU - Michalski, Jeff
AU - Zoberi, Jacqueline E.
AU - Kiess, Ana P.
AU - Spratt, Daniel E.
N1 - Funding Information:
Sources of support: This work had no specific funding. Disclosures: Dr Spratt received payment or honoraria from AstraZeneca, Bayer, Blue Earth, Boston Scientific, Novartis, Janssen, Gammatile, and Varian Medical Systems outside the submitted work. Dr Baumann received payment or honoraria from Boston Scientific, Varian Medical Systems, Galera Therapeutics, Mevion, and Regeneron/Sanofi outside the submitted work and is a board member of the National Association of Proton Therapy. Dr Zaorsky is supported by the National Institutes of Health grant LRP 1 L30 CA231572-01 and the American Cancer Society–Tri State CEOs Against Cancer Clinician Scientist Development grant CSDG-20-013-01-CCE, and received remuneration from Springer Nature for his textbook, Absolute Clinical Radiation Oncology Review. All other authors have no disclosures to declare.
Publisher Copyright:
© 2022 American Society for Radiation Oncology
PY - 2022/7/1
Y1 - 2022/7/1
N2 - Prostate-specific membrane antigen is a transmembrane protein found predominately on prostate epithelium and is expressed at high levels in prostate cancer. In this review, we discuss the background, clinical data, patient selection, side effects, and necessary resources to deliver lutetium-177 prostate-specific membrane antigen in the research setting, or as standard of care if approved by the United States Food and Drug Administration. Targeted radionuclide therapeutics require understanding of fundamental principles of radiobiology and physics, and radiation oncologists and medical physicists are well-suited to play an integral role in their delivery and treatment response monitoring as key components of a multidisciplinary care team.
AB - Prostate-specific membrane antigen is a transmembrane protein found predominately on prostate epithelium and is expressed at high levels in prostate cancer. In this review, we discuss the background, clinical data, patient selection, side effects, and necessary resources to deliver lutetium-177 prostate-specific membrane antigen in the research setting, or as standard of care if approved by the United States Food and Drug Administration. Targeted radionuclide therapeutics require understanding of fundamental principles of radiobiology and physics, and radiation oncologists and medical physicists are well-suited to play an integral role in their delivery and treatment response monitoring as key components of a multidisciplinary care team.
UR - http://www.scopus.com/inward/record.url?scp=85132241147&partnerID=8YFLogxK
U2 - 10.1016/j.prro.2022.01.012
DO - 10.1016/j.prro.2022.01.012
M3 - Article
C2 - 35717043
AN - SCOPUS:85132241147
SN - 1879-8500
VL - 12
SP - 294
EP - 299
JO - Practical Radiation Oncology
JF - Practical Radiation Oncology
IS - 4
ER -